This invention relates to the extraction of psychoactive compounds from psychedelic organisms for use in medicine. Raw psychedelic organisms are dried and pulverized. The psychoactive compounds are extracted using a solvent to result in an extraction slurry. The extraction slurry is filtered and pH-adjusted if necessary. The filtrate is then standardized to provide, when dried, a known concentration of the psychoactive alkaloids that have been extracted. The solvent is then evaporated from the filtrate to form the extract. The extract may be mixed with water and spray dried. The standardization process is run before or after full or partial evaporation of the solvent. The result is a powdered extract with a precisely defined concentration of psychoactive compounds.

The present disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids, an effective amount of a compound (e.g., psilocybin/psilocin) for treating drug addiction (e.g. opioid addiction) and menthol where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. The present disclosure also disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and menthol as well as carboxymethyl cellulose, carrageenan and a cross-linking agent.

Disclosed herein are methods of extracting active agents from fungi, in particular psychedelic and functional fungi, and including methods of extracting active agents from fungi using certain natural solvents at particular defined parameters to make extracts and products therefrom having increased palatability and reduced unwanted side effects compared to known extracts and products. Also disclosed are medicinal food and beverage products comprising extracts with one or more active agents obtained using the disclosed methods, as well as methods of their use, such as to produce an effect, or to treat a condition or disorder.

A composition for upregulating the immune system, endocannabinoid system and main bodily systems while promoting mental stability for optimal wellness. Also provided is a method for enhancing/stimulating the immune, endocannabinoid and/or main bodily systems of a patient, particularly a mammal with a disease or disorder, which includes a step of administering the composition to the patient. The composition includes a combination of Mushroom Spore Oil and/or Spore Powder and at and at least one of b1) a cannabinoid, b2) DMSO/Dimethyl Sulfoxide, b3) minerals, b4) botanicals, b5) Vitamins, b6) Amino Acids, and b7) fungi.

Provided are therapeutic combinations, pharmaceutical compositions, and pharmaceutical kits comprising fungi (e.g., Psilocybe spp. fungi), plants (e.g., Cannabis spp., Dipteryx spp.), and algae (e.g., from the family Bangicaeae, including Pyropia spp. and Porphyra spp.), including extracts and bioactive molecules derived therefrom. Methods of producing the disclosed combinations, compositions, and kits are also provided, such as using natural, biosynthetic, or synthetic means. Further provided are methods of using the disclosed combinations, compositions, and kits in the treatment of medical conditions, and in particular for treating inflammatory diseases and conditions, for which the disclosed combinations are demonstrated to provide significant advantages.

Provided herein are methods for treating a patient with ADHD and anxiety, comprising administering to the patient a therapeutically effective amount of psilocybin. The disclosure also provides methods for treating ADD and reducing symptoms of Tourette Syndrome using psilocybin. Additionally, methods of cultivation, extraction, and purification of psilocybin mushrooms are described. The psilocybin is obtained from mushroom species such as Psilocybe cubensis, Psilocybe cyanescens, Psilocybe semilanceata, or Psilocybe azurescens. The methods involve tissue culture, agar inoculation, grain-to-grain transfer, bulk substrate inoculation, and fruiting. Extraction and purification steps include harvesting, drying, grinding, solvent extraction, filtration, evaporation, and cryogenic separation.

The present invention provides genetically modified fungi, such as non-hallucinogenic psychedelic fungi, in which a biochemical pathway to produce a bioactive alkaloid is disrupted. In some aspects, the psilocybin biosynthesis pathway is disrupted, resulting in non-hallucinogenic psychedelic fungi which do not produce or contain psilocybin, or which produce or contain a substantially reduced amount of psilocybin relative to wild-type fungi. Also provided are methods of making genetically modified fungi, for example by disrupting or rebalancing a biochemical pathway therein, such as the psilocybin biosynthesis pathway, such as by using gene editing techniques, including gene inactivation by small interfering RNAs (siRNAs), microRNAs (miRNAs), and CRISPR/Cas9. Also provided are compositions of genetically modified fungi, such as compositions of non-hallucinogenic psychedelic fungi, and methods of their use, including as functional foods, nootropics, legal microdoses, nutraceuticals, and therapeutics.

A system for extracting substances from a source material includes a chamber assembly, one or more ultrasonic transducers, and one or more convective mixing mechanisms. The chamber assembly defines a chamber. The chamber is configured to hold source material and a solvent such that at least a portion of the source material is immersed in the solvent. The one or more ultrasonic transducers are configured to produce ultrasonic waves that impinge on at least a portion of the portion of the source material in the solvent. The one or more mixers are configured to mix at least a portion of the source material.

Provided are therapeutic combinations, pharmaceutical compositions, and pharmaceutical kits comprising bioactive molecules from fungi, plants, and algae. In some embodiments, the fungi are from any psilocybin-producing fungi, such as from Psilocybe spp. fungi. In some embodiments, the plants are from either or both of the Cannabis and Dipteryx genera. In some embodiments, the algae may be marine algae, such as from the family Bangicacae, including the Pyropia and Porphyra genera. Methods of producing the disclosed combinations, compositions, and kits are also provided, such as using natural, biosynthetic, or synthetic means. Further provided are methods of using the disclosed combinations, compositions, and kits in treatment, and in particular for movement disorders, such as for Parkinson's disease, and the disclosed combinations are demonstrated to provide significant advantages in the treatment thereof.